Glowing cancer tool illuminates benign, but dangerous, brain tumors during pituitary surgery

September 5, 2017, Perelman School of Medicine at the University of Pennsylvania
John Y.K. Lee, MD, MSCE, an associate professor of Neurosurgery in the Perelman School of Medicine at the University of Pennsylvania and co-director of the Center for Precision Surgery. Credit: Penn Medicine

An experimental imaging tool that uses a targeted fluorescent dye successfully lit up the benign brain tumors of patients during removal surgery, allowing surgeons to identify tumor tissue, a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania shows. The tumors, known as pituitary adenomas, are the third most common brain tumor, and very rarely turn cancerous, but can cause blindness, hormonal disorders, and in some cases, gigantism.

Findings from the pilot study of 15 patients, published this week in the Journal of Neurosurgery, build upon previous clinical studies showing intraoperative molecular imaging developed by researchers at Penn's Center for Precision Surgery can improve surgeries. According to first author John Y.K. Lee, MD, MSCE, an associate professor of Neurosurgery in the Perelman School of Medicine at the University of Pennsylvania and co-director of the Center for Precision Surgery, this study describes the first targeted, near infrared dye to be employed in . Other dyes are limited either by their fluorescent range being in the busy visible spectrum or by lack of specificity.

"This study heralds a new era in personalized tumor surgery. Surgeons are now able to see molecular characteristics of patient's tumors; not just light absorption or reflectance," Lee said. "In real time in the , we are seeing the unique cell surface properties of the tumor and not just color. This is the start of a revolution."

Non-specific dyes have been used to visualize and precisely cut out brain tumors during resection surgery, but this dye is believed to be the first targeted, near infrared dye to be used in neurosurgery. The fluorescent dye, known as OTL38, consists of two parts: vitamin B9 (a necessary ingredient for cell growth), and a near infrared glowing dye. As tumors try to grow and proliferate, they overexpress folate receptors. Pituitary tumors can overexpress folate receptors more than 20 times above the level of the normal pituitary gland in some cases. This dye binds to these receptors and thus allows us to identify tumors.

"Pituitary adenomas are rarely cancerous, but they can cause other serious problems for patients by pushing up against parts of their brain, which can lead to Cushing's disease, gigantism, blindness and death," Lee explained. "The study shows that this novel, targeted, near infrared fluorescent dye technique is a safe, and we believe this technique will improve surgery."

Lee says larger studies are warranted to further demonstrate its clinical effectiveness, especially in nonfunctioning .

A big challenge with this type of brain surgery is ensuring the entire tumor is removed. Parts of the tumor issue are often missed by conventional endoscopy approaches during removal, leading to a recurrence in 20 percent of patients. The researchers showed that the technique was safe and effective at illuminating the molecular features of the tumors in the subset of patients with nonfunctioning pituitary adenomas.

The technique uses near-infrared, or NIR, imaging and OTL38 fluoresces brightly when excited by NIR light. The VisionSense IridiumTM 4mm endoscope is a unique camera system which can be employed in the narrow confines of the nasal cavity to illuminate the pituitary adenoma. Both the dye and the camera system are needed in order to perform the surgery successfully.

The rate of gross-total resection (GTR) for the 15 patients, based on postoperative MRI, was 73 percent. The GTR with conventional approaches ranges from 50 to 70 percent. Residual tumor was identified on MRI only in patients with more severe tumors, including cavernous sinus invasion or a significant extrasellar tumor.

In addition, for the three patients with the highest overexpression of folate, the technique predicted post-operative MRI results with perfect concordance.

Some centers have resorted to implementing MRI in the operating room to maximize the extent of resection. However, bringing a massive MRI into the operating room theater remains expensive and has been shown to produce a high number of false-positives in pituitary adenoma . The fluorescent dye , Lee said, may serve as a replacement for MRIs in the operating room.

Co-authors on the study include M. Sean Grady, MD, chair of Neurosurgery at Penn, and Sunil Singhal, MD, an associate professor of Surgery, and co-director the Center for Precision Surgery.

Over the past four years, Singhal, Lee, and their colleagues have performed more than 400 surgeries using both nonspecific and targeted near infrared dyes. The breadth of tumor types include lung, brain, bladder and breast.

Most recently, in July, Penn researchers reported results from a lung cancer trial using the OTL38 dye. Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients with the dye using preoperative positron emission tomography, or PET, scans. Penn's imaging tool identified 60 of the 66 previously known lung nodules, or 91 percent. In addition, doctors used the tool to identify nine additional nodules that were undetected by the PET scan or by traditional intraoperative monitoring.

Researchers at Penn are also exploring the effectiveness of additional contrast agents, some of which they expect to be available in the clinic within a few months.

"This is the beginning of a whole wave of new dyes coming out that may improve surgeries using the technique," Lee said. "And we're leading the charge here at Penn."

Explore further: Glowing tumor technology helps surgeons remove hidden cancer cells

More information: Journal of Neurosurgery (2017). thejns.org/doi/full/10.3171/2017.2.JNS163191

Related Stories

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

Glowing tumors help Penn surgeons cut out brain cancer with precision

November 16, 2016
An experimental cancer imaging tool that makes tumors glow brightly during surgery has shown promise again in a new Penn Medicine clinical study, this time in patients with brain cancer. The fluorescent dye technique, originally ...

New imaging technique could ID additional ovarian tumors not visible to surgeons' eyes

June 15, 2016
A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during ...

Technology that helps surgeons see cancer tissue being tested

October 23, 2013
OnTarget Laboratories LLC has teamed with partners in academia to test a novel optical imaging technology developed at Purdue University that could help surgeons see cancer tissue during surgery.

An especially challenging brain cancer diagnosis

August 24, 2017
Most brain cancers start elsewhere in the body, but one particularly aggressive and uncommon form—glioblastoma—originates in the brain itself.

Researchers use infrared imaging to detect lung tumors

September 25, 2014
Penn Medicine researchers are now able to identify cancerous tumors of the lung using infrared imaging that makes hidden tumors glow during surgery. In a pilot study, researchers performed the first in-human demonstration ...

Recommended for you

Clues found to early lung transplant failure

May 21, 2018
Among organ transplant patients, those receiving new lungs face a higher rate of organ failure and death compared with people undergoing heart, kidney and liver transplants. One of the culprits is inflammation that damages ...

Blood type O patients may have higher risk of death from severe trauma

May 1, 2018
Blood type O is associated with high death rates in severe trauma patients, according to a study published in the open access journal Critical Care that involved 901 Japanese emergency care patients.

Brains, eyes, testes: off-limits for transplants?

April 28, 2018
Since the world's first successful organ transplant in 1954—a kidney—the discipline has advanced to the point where a wounded soldier could have his penis and scrotum replaced in a groundbreaking operation last month.

Emergency treatment by older surgeons linked to slightly lower death rates

April 26, 2018
Patients undergoing emergency surgery who are treated by older surgeons (aged 60 or over) have slightly lower death rates in the first few weeks after their operation than patients treated by younger surgeons (aged less than ...

Bionic suit helps paralyzed patients stand and walk again

April 25, 2018
Patients undergoing physical rehabilitation at Rush for paralyzing injuries are being aided by a robotic suit designed to help raise people to full height and walk.

Johns Hopkins performs first total penis and scrotum transplant in the world

April 23, 2018
Many soldiers returning from combat bear visible scars, or even lost limbs, caused by blasts from improvised explosive devices, or IEDs. However, some servicemen also return with debilitating hidden injuries—the loss of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.